Neuroblastoma stage 4S: Tumor regression rate and risk factors of progressive disease by Tas, M.L. (Michelle L.) et al.
Received: 28May 2019 Revised: 19 September 2019 Accepted: 9 October 2019
DOI: 10.1002/pbc.28061 Pediatric
Blood &
Cancer The American Society ofPediatric Hematology/OncologyR E S E A RCH ART I C L E
Neuroblastoma stage 4S: Tumor regression rate and risk
factors of progressive disease
Michelle L. Tas1 Michelle Nagtegaal2 Kathelijne C.J.M. Kraal1
Godelieve A.M. Tytgat1,2 Nico G.G.M. Abeling3 SaskiaM.F. Pluijm1
C.Michel Zwaan1,4 Bart de Keizer1,5 Jan J. Molenaar1 MaxM. van
Noesel1
1PrincessMáxima Center for Pediatric Oncology, Utrecht, The Netherlands
2Department of Social Pediatrics, EmmaChildren’s Hospital/AmsterdamUniversityMedical Centers, Amsterdam, The Netherlands
3Laboratory for GeneticMetabolic Diseases, AmsterdamUniversityMedical Centers, Amsterdam, The Netherlands
4Department of Pediatric Oncology, ErasmusMedical Center, Sophia Children’s Hospital, Rotterdam, The Netherlands
5Department of Radiology andNuclearMedicine, UniversityMedical Center Utrecht, Utrecht, The Netherlands
Correspondence
Michelle L. Tas, PrincessMáximaCenter for
PediatricOncology,Heidelberglaan25, 3584CS
Utrecht, TheNetherlands.
Email:m.tas@prinsesmaximacentrum.nl
This paperwaspreviously publishedas ameeting
abstract at:
1.Neuroblastomastage4S: regression rate and
patients at risk, SIOP14-10-2017,PediatrBlood
Cancer. 2017; 64 (S3)
2.Neuroblastomastage4S: regression
rate andpatients at risk,ANR10-5-2018,
https://www.anrmeeting.org/dl/ANR2018/ANR
_Abstract_Book_5-3-18.pdf
Funding information
Villa JoepFoundation; StichtingKinderen
Kankervrij
Abstract
Background: The clinical course of neuroblastoma stage 4S or MS is characterized by a high rate
of spontaneous tumor regression and favorable outcome. However, the clinical course and rate of
the regression are poorly understood.
Methods: A retrospective cohort study was performed, including all patients with stage 4S neu-
roblastoma without MYCN amplification, from two Dutch centers between 1972 and 2012.
We investigated the clinical characteristics, the biochemical activity reflected in urinary cate-
cholamineexcretion, and radiological imaging todescribe thekineticsof tumor regression, therapy
response and outcome.
Results: The cohort of 31 patients reached a 10-year overall survival of 84% ± 7% (median
follow-up 16 years; range, 3.3-39). During the regressive phase, liver size normalized in 91% of
the patients and catecholamine excretion in 83%, both after a median of two months (liver size:
range, 0-131; catecholamines: range, 0-158). The primary tumors completely regressed in 69%
after 13 months (range, 6-73), and the liver architecture normalized in 52% after 15 months
(range, 5-131). Antitumor treatment was given in 52% of the patients. Interestingly, regression
rates were similar for treated and untreated patients. Four of seven patients < 4 weeks old died
of rapid liver expansion and organ compression. Three patients progressed to stage 4, 3 to 13
months after diagnosis; all had persistently elevated catecholamines.
Conclusion: Patients < 4 weeks old with neuroblastoma stage 4S are at risk of fatal outcome
caused by progression of liver metastases. In other patients, tumor regression is characterized by
a rapid biochemical normalization that precedes radiological regression.
Abbreviations: 131I-MIBG, iodine-131-metaiodobenzylguanidine; 4S, 4 special; CR, complete remission; EFS, event-free survival; HVA, homovanillic acid; INRC, International Neuroblastoma
Response Criteria; MS, metastatic special; NCA, numerical chromosomal aberrations; OS, overall survival; PR, partial remission; SCA, segmental chromosomal aberrations; VGPR, very good
partial remission; VMA, vanillylmandelic acid.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any
medium, provided the original work is properly cited, the use is non-commercial and nomodifications or adaptations aremade.
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1 INTRODUCTION
Neuroblastoma stage 4S (S for “Special”) defined patients< 12months
old with primary tumors stage 1 or 2 and dissemination limited
to specific sites, such as liver, bone marrow (< 10% invasion), and
skin.1 In the International Neuroblastoma Risk Group Staging System
(INRGSS), the age limit was extended to 18months, and primary tumor
stage was not taken into account anymore.2 In all staging systems,
osteomedullary tracer uptake on 99Tc bone scans or 123I-MIBG scans
defines stage 4. Stage 4S is characterized by a favorable course of dis-
ease and a high rate of spontaneous tumor regression.1–3 Long-term
survival rates are estimated between 65%and92%.4–7 In general, neu-
roblastoma 4S can be managed by active surveillance in expectation
of spontaneous tumor regression. In patients with symptoms of organ
compression, antitumor treatment (chemotherapy or low-dose radio-
therapy to the liver) is advised. Although the tumor regresses in most
patients, very young patients are at risk of early and rapid progres-
sion of livermetastases, causing life-threatening compression of lungs,
kidneys, inferior vena cava, normal liver tissue, and intestines.8 Tumor
progression to true stage 4 or high-risk disease is seen occasionally.
This can occur before complete regression and is different from late-
onset recurrent disease.
Previously, we explained regression as a process of delayed dif-
ferentiation of tumor nodules.9 We consider stage 4S as a multifocal
developmental disease with an onset in the early stage of neural crest
development. (Pre)migratory neural crest cells suffer fromadefect and
spread to different target organs of the neural crest (skin, liver, bone
marrow, adrenal glands, sympathetic side chain) to form proliferative
tumor nodules. The tumor regression reflects a delayed step of cellular
differentiation and apoptosis.9 The process and clinical regression rate
have not been studied for the expected time to normalization ondiffer-
ent modalities. Also, it is not clear if antitumor treatment (chemother-
apy and radiotherapy) has any effect on the initiation of the regression
process.
Here, we studied the survival rates, frequency, and rate of tumor
regression in a retrospective cohort of patients with neuroblastoma
stage 4S. We describe risk factors of progressive disease. Finally, we
evaluated the effect of therapy on disease regression.
2 METHODS
2.1 Patient cohort
The Erasmus Medical Center’s and Amsterdam University Medical
Centers’ Pediatric Oncology databases were reviewed to identify all
patients diagnosed with neuroblastoma stage 4S1 or MS2 between
1972 and 2012. Patients diagnosed with stage 4 aged 12 to 18
months were reviewed for MS criteria. The term 4S was used for this
study, because all patients met these criteria. Shallow whole-genome
sequencing was performed as described previously.10
2.2 Clinical outcome
Tumor response was evaluated according to the International Neu-
roblastoma Response Criteria (INRC)1 at last moment of follow-up.
For the purpose of this study, we classified three types of progres-
sion: (A) fast initial tumor progression with increase of liver mass,
(B) tumor progression to stage 4 neuroblastoma < 5 years from
diagnosis, (C) late recurrent disease after > 5 years. Initial treatment
was according to local protocols; all protocols were based on a wait-
and-see approach, unless life-threatening symptoms or complications
occurred. Chemotherapy regimens differed over time but in general
consisted of cyclophosphamide and vincristine. From 2009 onward,
all treated patients are given the combination of cyclophosphamide,
vincristine, and doxorubicin. Used chemotherapeutics are listed per
patient in Supporting Information Table S3. Patients with progres-
sion to stage 4 aged < 1 year at time of progression were upstaged
to medium-risk protocols, and patients aged ≥ 1 year to high-risk
protocols. To compare the therapy effect on regression, regression
kinetics of treated patients were compared with untreated patients.
Surgery-only patients were analyzed in the untreated group, because
surgery will not have influenced regression of metastases.
2.3 Radiological evaluation
All radiological and nuclear scan reports were reviewed (MT and BdK).
For the liver, both size and architecture were evaluated. Liver size
was compared with age-related reference levels.11 No strict intervals
for follow-up were defined until 2009. Ultrasounds in patients with
hepatomegaly were performed biweekly or monthly in the first two
months, expanding to every two months until six months after diag-
nosis, followed by undefined regular follow-up. 123I-MIBG and MRI
scanswere performed every twomonths from2009 onward, andwith-
out defined follow-up intervals before 2009. CT scans were rarely
performed or in low dose in combination with 123I-MIBG scanning.
Patientswith an event (progression and death)were excluded from the
long-term regression analysis.
2.4 Metabolic evaluation
Urinary homovanillic acid (HVA) and vanillylmandelic acid (VMA)were
measured and reported (fold change of the upper limit for age; defined
as mean +2 SD) as described previously.12 Time from diagnosis to last
abnormal value was used instead of time to normalization. This prob-
ably represented a more accurate time to normalization because the
lack of standardized intervals occasionally resulted in long periods
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between last abnormal (but slightly elevated values) and first normal
values. Additionally, a few patients maintained elevated HVA (n = 4)
or VMA (n = 3) excretion levels even after years of follow-up. By using
time to first normal measurement, we would have to exclude these
patients, causing information bias.
2.5 Statistical analysis
Statistical analysis was performed using the statistical program SPSS
25 (IBM Corp., Armonk, NY). Estimated 10-year overall survival (OS)
and event-free survival (EFS) rates were calculated according to
Kaplan-Meier survival analysis and are reported ±SE. Follow-up time
was defined as the time of diagnosis to any event, death, or last follow-
up. Fisher exact test and theMann-WhitneyU test were used for com-
parisons between treated and untreated patients. P values of < 0.05
were considered statistically significant.
3 RESULTS
3.1 Patient characteristics
We identified 35 patients with the clinical diagnosis of neuroblastoma
stage 4S, representing 8% of total neuroblastoma diagnoses. After
exclusion of patients with MYCN amplification (n = 4), 31 patients
were included (Supporting Information Table S1). The median age
at diagnosis was 70 days (range, 1-228 days). Seven (23%) patients
were < 4 weeks old. The primary tumor was located in the adrenal
gland in 23 (74%) (five patients had bilateral adrenal tumors), in the
sympathetic side chain in 5 (16%) patients, and remained unknown
in 3 (10%) patients. All patients except one had liver metastases, and
5 (16%) had skin metastases. Bone marrow was evaluated in 28
patients and infiltrated in 7 (25%) (Table 1). Antitumor treatment was
given in 16 (52%) patients: 12 (39%) patients received chemotherapy,
7 (23%) received Iodine-131-Metaiodobenzylguanidine (131I-MIBG)
therapy, 6 (19%) received radiotherapy, and the primary tumor was
surgically removed in 5 (16%) patients (Supporting Information Table
S1). One patient was presented in a case report previously.13
3.2 Survival and response
The 10-year OS and EFS rates were 84% ± 7% and 69% ± 9%
(Figure 1A), respectively. At last follow-up, 18 (58%) patients had
reached complete remission (CR), 8 (26%) (very good) partial remission
((VG)PR), and 5 (16%) had died of neuroblastoma. This was similar in
treated and untreated patients (Table 1).
3.3 Tumor regression
Adrenal/sympathetic side chain tumor: Evaluation of primary tumor
regression was feasible in 16 of 31 patients. For 15 patients, follow-up
was not feasible because of progressive disease (n=7), resection of the
primary tumor (n= 5), or an unknown primary tumor (n= 3). Complete
regressionwas achieved in 11 (69%) of 16 patients, after amedian time
of 13 months (range, 6-73 months; Figure 2), while residual lesions
persisted in 5 (31%) patients (Table 1). Primary tumor regression was
comparable in treated and untreated patients (63% vs. 75%%, 15 vs. 9
months, respectively; Table 1). Interestingly, complete regression was
achieved in 92% of the adrenal tumors, while in 0% of the sympathetic
side chain tumors (P< 0.01).
3.3.1 Liver
Regression of liver metastases was studied in 23 of 30 patients with
liver metastases. For seven patients, follow-up was not possible
because of progressive disease. Liver size normalized in 21 (91%)
patients, after a median of two months (range, 0-131) (Figure 2). No
difference was observed between treated and untreated patients
(91% vs 92%; 10 vs 2 months; P = 0.31). Liver architecture normalized
in 12 (52%) of the patients, after a median time of 14.5 months (range,
5-131 months). Again, no difference was observed between treated
and untreated patients (45% vs 58%, P = 0.68; 17 vs 14 months,
P = 0.45). In 11 (48%) patients, both the size and architecture of the
liver completely normalized.
3.3.2 Metabolic regression
Regression of the catecholamines HVA and VMA was studied in 24 of
31patients. In theother sevenpatients, excretion levelswerenot avail-
able because of rapid progression (n=4) or before thiswas standard of
care (n= 3). HVA levels normalized in 20 (83%) patients andVMA in 21
(88%) patients. Last abnormal values weremeasured after a median of
2.2 months for HVA (range, 0-158) and 1.6 months for VMA (range, 0-
158) (Figure 2), whichwas comparable between treated and untreated
patients (P= 0.32 and P= 0.14, respectively) (Table 1).
3.4 Progressive disease
Patients with progressive disease were subcategorized in three types
of progression. Four patients died of fast initial tumor progression
(type A). Three patients progressed to stage 4 disease < 5 years from
diagnosis (type B), one of them died of disease, and two are in CR after
additional treatment. Two patients suffered from late relapses (type
C): one with stage 4 disease without MYCN amplification who is in CR
after high-risk treatment; the other with a localized ganglioneuroma,
which has been stable without further treatment.
3.4.1 Type A progression: fast initial tumor progression
with increase of the livermass
Liver metastases and hepatomegaly were present in 30 and 21
patients, respectively. Six patients (4 patients < 4 weeks old) devel-
oped respiratory distress requiringmechanical ventilation (Figure 1B).
All four very young patients died within three weeks after diagnosis
of multiple organ failure due to organ compression. Two of them were
treated with cyclophosphamide and vincristine without effect on liver
mass or respiration. The other two patients < 4 weeks old did not
receive antitumor treatment because of poor clinical condition; they
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F IGURE 1 Kaplan-Meier estimates of survival of the neuroblastoma stage 4S patients. 10-year EFS and theOS of all patients; (A) 10-year EFS
(red line; 69%± 9%) andOS (blue line; 84%± 7%). (B) 10-year EFS according to age groups (red line< 4weeks old at diagnosis [n= 7] 43%± 19%;
blue line≥4weeks [n= 24] 77%± 9%; P= 0.02). (C) 10-year OS according to age groups (red line< 4weeks old [n= 7] 43± 19%; blue line
≥4weeks [n= 24] 96%± 4%; P< 0.001)
died within two days after admission. The two older patients, 6 weeks
and 6 months old, survived. In total, four of seven patients < 4 weeks
old (58%) died of type A progression, resulting in a significant higher
risk of dying due to type A progression for younger than for older
patients (Figure 1C; log-rank P< 0.001).
3.4.2 Type B progression: progression to stage 4 disease
< 5 years from diagnosis
Type B progression occurred in three patients—3, 8, and 13 months
after initial diagnosis—and was fatal in one patient despite high-risk
treatment (Table 1). The remaining two patients are in CR, 99 and 108
months after progression. In none of the patients with type B progres-
sion, catecholamine excretion normalized prior to the progression. In
contrast, patients with no progression and finally CR, catecholamines
normalized after 1.2 months (range, 0-8.9 months) for HVA and 0.7
months (range, 0-4.2 months) for VMA (Figure 3; type B progression
vs CR: P= 0.02 for HVA, P< 0.01 for VMA).
3.4.3 Type C progression: late recurrent disease
after> 5 years
TypeCprogression occurred in 2 patients: one suffered from recurrent
stage 4 disease, without MYCN amplification, 69 months after initial
neuroblastoma 4S diagnosis. This patient is currently, 97 months after
progression, in CR after high-risk treatment. The other patient devel-
oped a new tumor nodule in a previously unaffected site, 119 months
after initial neuroblastoma 4S diagnosis. Biopsy revealed a ganglioneu-
roma, and the tumor remained stable without treatment until last
follow-up 143months later.
3.5 Copy-number analysis
Twenty tumors were evaluated for numerical chromosomal aberra-
tions (NCA; whole chromosome gains and losses) and for segmental
chromosomal aberrations (SCA; partial gains and losses).14 No tumor
material was available for patients with type A progression. Two
of three patients with type B progression had isolated SCA, while
none of the progression-free patients had isolated SCA (Supporting
Information Table S2). The patient with type C stage 4 progression had
both NCA and SCA at the time of 4S diagnosis. In this limited cohort,
significant differences were observed in EFS when patients were
classified in the different genomic pattern groups. Patients with only
NCA had a 10-year EFS of 89% ± 11%, patients with both NCA and
SCA had a 10-year EFS of 86% ± 13%, and patients with only SCA had
a significantly poorer 10-year EFS 0% (log-rank P < 0.01; Supporting
Information Figure S1).
4 DISCUSSION
We performed a retrospective cohort study investigating the regres-
sion kinetics and risk factors of progression in patients with stage
4S neuroblastoma. In this cohort of 31 patients, the 10-year OS
was 84% ± 7%. Catecholamine excretion and liver size normaliza-
tion occurred in 83% and 91% of the patients after a median of two
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TABLE 1 Patient characteristics at diagnosis and outcome, compared between untreated and treated patients
Untreated n/N (%) Treated n/N (%) Significance (P)
Patient characteristics at diagnosis
Gender: male 9/15 (60.0) 7/16 (43.8) 0.48
Age< 1month 5/15 (33.3) 2/16 (12.5) 0.22
Age (median days, range) 70 (1-228) 78 (2-186) 0.29
Primary tumor NA
Adrenal 11/15 (73.3) 12/16 (75.0)
Sympathetic side chain 2/15 (13.3) 3/16 (18.8)
Unknown 2/15 (13.3) 1/16 (6.3)
Liver metastases 15/15 (100) 15/16 (93.8) NA
Skinmetastases 2/15 (13.3) 3/16 (18.8) NA
Bonemarrowmetastases 2/12 (16.7) 5/16 (31.3) 0.66
Fold change of HVA at diagnosis (median) 3.67 (n= 12) 13.35 (n= 10) 0.12
Fold change of VMA at diagnosis (median) 4.61 (n= 12) 13.33 (n= 10) 0.12
MYCN amplification status unknown 5/15 (33.3) 4/16 (25.0) 0.70
LOH1p (n= 21) 2/9 (22.2) 3/12 (25.0) NA
Outcome characteristics
Progression 0.60
No progression 12/15 (80.0) 10/16 (62.5)
Type A 2/15 (13.3) 2/16 (12.5)
Type B 1/15 (6.7) 2/16 (12.5)
Type C 0/15 (0.0) 2/16 (12.5)
INRC at last follow-up NA
CR 9/15 (60.0) 9/16 (56.3)
(VG)PR 4/15 (26.7) 4/16 (25.0)
PDa 2/15 (13.3) 3/16 (18.8)
Primary tumor NA
Complete regression 6/8 (75) 5/8 (62.5)
Residual lesion 2/8 (25) 3/8 (37.5)
Liver NA
Normalization 6/12 (50.0) 5/11 (45.5)
Parenchymal aberrations and/or hepatomegaly 6/12 (50.0) 6/11 (54.5)
Last abnormal HVA (months, median) 1.2 (n= 12) 3.5 (n= 12) 0.32
Last abnormal VMA (months, median) 0.3 (n= 12) 2.2 (n= 12) 0.14
First normal HVA (months, median) 6.7 (n= 11) 6.2 (n= 9) 0.67
First normal VMA (months, median) 5.4 (n= 11) 6.3 (n= 10) 0.62
Abbreviations: CR, complete remission; HVA, homovanillic acid; LOH, loss of heterozygosity, INRC, International Neuroblastoma Response Criteria; NA, not
applicable; PD, progressive disease; (VG)PR, (very good) partial remission; VMA, vanillylmandelic acid.
aAll patients with progressive disease at last follow-up died of disease.
months. Primary tumors and liver architecture normalized in 69% and
52% after a median of 13 and 15 months, respectively (Figure 2).
Patients < 4 weeks old are at risk of a fatal outcome due to massive
progression of liver metastases and subsequent organ compression.
Normalization of liver architecture has been reported by Levitt
et al. and French et al., who describe liver architecture normalization
in 42% and 48% of 28 and 15 patients, respectively.15,16 One study
described liver size normalization in < 12 months in two patients.17
Early expansion of liver metastases caused respiratory distress requir-
ing mechanical ventilation in 19% of patients in the first weeks after
diagnosis. It was only fatal in children<4weeks old. In our cohort, 58%
of the patients< 4weeks died of type A progression, while none of the
patients ≥4 weeks did (P < 0.001). In six previous studies6,8,18–21 with
a total of 506 NB4S patients, 45 patients died of what we describe as
type A progression. Of these 45 children, 93% were < 2 months old at
diagnosis. A recent report of patientswith symptomatic disease and/or
unfavorable histology showed a 13 times increased risk of fatal out-
come in patients younger than 40 days compared with patients older
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than 47 days.22 These and our study lead to the conclusion that chil-
dren< 2months at diagnosis are at risk of dying of type A progression.
They should be monitored closely, and starting antitumor treatment
should be considered at onset of symptoms. Older children are hardly
at risk for a fatal outcome due to type A progression, even if the liver
nodules show initial progression.
Antitumor treatment is given in patients with type A progression
in an attempt to induce tumor regression to prevent clinical compli-
cations of organ compression. However, its effectiveness has never
been proven. Here, the commonly used combination of vincristine and
cyclophosphamide did not result in arresting the progression in the
two treated young patients. Additionally, we observed no difference
in the outcome or the regression rate of patients with or without
treatment. Although this is a retrospective study with a limited num-
ber of patients, which hampers a proper analysis of baseline differ-
ences in tumor load, the question is raised whether antitumor ther-
apy influences the outcome or regression in very young children with
this type of early progression, and if antitumor treatment is needed
in older stage 4S patients. Moreover, a recent large prospective study
could not establish an effect of chemotherapy on tumor regression or
outcome.22 Considering the concept of delayed differentiation of early
neural crest cells and subsequent differentiation,9 the question is valid
if chemotherapy can accelerate the differentiation and regression pro-
cess or if it can halt the progression. Therefore, it would be best to
study (early) response kinetics in detail in a prospective cohort.
The retrospective design and the long inclusion period are obvi-
ous limitations of the study. In this 40-year period, improvements have
been achieved in the quality and availability of imaging techniques
and other diagnostics. Supportive care and treatment protocols have
also been improved; our current treatment protocol contains doxoru-
bicin in addition to cyclophosphamide and vincristine. Still, one of the
patients who died of type A progression was diagnosed in 2011, when
allmodern imagingmodalitieswere present and our current treatment
protocol was standard care.
All patients with type B progression to stage 4 disease retained ele-
vated catecholamine excretion until tumor progression was observed,
suggesting that these tumors are biologically different from tumors
that regress. A different biology is also suggestedby thehigher number
of patients with structural chromosomal aberrations.23 This is consis-
tent with earlier reports that tumors with segmental aberrations have
a more aggressive disease.14,23,24 Because CNA was tested in only a
small number of patients in this study, we cannot draw definitive con-
clusions. However, in the ongoing European LINES trial, the effect of
the CNA in this group is being prospectively studied. Recent research
concluded that the combination of telomere maintenance activity and
aberrations in the RAS and TP53 pathways can predict unfavorable
outcome in low-risk patients.25 It would be interesting to see if these
parameters are helpful in making treatment decisions.
In conclusion, patients with neuroblastoma stage 4S have a favor-
ableoutcomeasa result of spontaneous tumor regression.Biochemical
regression precedes radiological normalization and is usually reached
within the first months. Children < 2 months old at diagnosis are at
risk of fatal outcome in the first weeks after diagnosis due to tumor
progression and it is strongly recommended towatch them closely and
consider treatment. The remainder of patients has a small chance to
progress to high-risk disease, especially when they have normalized
biochemical activity and no segmental gains and losses in their tumor
genome.
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